** Shares of medical device maker Tivic Health Systems TIVC.O rise 232.6% to $11.82 premarket
** TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates
** Both meetings were held last week in Washington D.C. - TIVC
** Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod
** Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation
** As of last close, TIVC had fallen 40.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.